Other OTC - Delayed Quote USD

Astellas Pharma Inc. (ALPMY)

9.55 +0.01 (+0.10%)
At close: April 26 at 3:59 PM EDT
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,543,324,000.00
1,518,619,000.00
1,296,163,000.00
1,249,528,000.00
Cost of Revenue
281,536,000.00
288,353,000.00
253,009,000.00
246,063,000.00
Gross Profit
1,261,787,000.00
1,230,266,000.00
1,043,154,000.00
1,003,465,000.00
Operating Expense
1,245,086,000.00
1,098,709,000.00
912,191,000.00
867,892,000.00
Operating Income
16,701,000.00
131,557,000.00
130,963,000.00
135,573,000.00
Net Non Operating Interest Income Expense
-116,000.00
-669,000.00
1,200,000.00
9,273,000.00
Pretax Income
25,753,000.00
132,361,000.00
156,886,000.00
145,324,000.00
Tax Provision
21,556,000.00
33,647,000.00
32,800,000.00
24,734,000.00
Net Income Common Stockholders
4,198,000.00
98,714,000.00
124,086,000.00
120,589,000.00
Diluted NI Available to Com Stockholders
4,198,000.00
98,714,000.00
124,086,000.00
120,589,000.00
Basic EPS
2.87
54.24
67.08
64.93
Diluted EPS
2.65
54.09
67.05
64.90
Basic Average Shares
1,797,429.75
1,820,019.00
1,849,713.00
1,857,125.00
Diluted Average Shares
1,806,631.25
1,825,061.00
1,850,602.00
1,858,193.00
Total Operating Income as Reported
25,869,000.00
133,029,000.00
155,686,000.00
136,051,000.00
Total Expenses
1,526,622,000.00
1,387,062,000.00
1,165,200,000.00
1,113,955,000.00
Net Income from Continuing & Discontinued Operation
4,198,000.00
98,714,000.00
124,086,000.00
120,589,000.00
Normalized Income
-3,281,552.00
98,555,848.00
104,916,906.00
120,589,000.00
Interest Income
9,775,000.00
8,110,000.00
6,149,000.00
11,608,000.00
Interest Expense
9,891,000.00
8,779,000.00
4,949,000.00
2,335,000.00
Net Interest Income
-116,000.00
-669,000.00
1,200,000.00
9,273,000.00
EBIT
35,644,000.00
141,140,000.00
161,835,000.00
147,659,000.00
EBITDA
167,858,000.00
246,878,000.00
241,519,000.00
220,311,000.00
Reconciled Cost of Revenue
281,536,000.00
288,353,000.00
253,009,000.00
246,063,000.00
Reconciled Depreciation
132,214,000.00
105,738,000.00
79,684,000.00
72,652,000.00
Net Income from Continuing Operation Net Minority Interest
4,198,000.00
98,714,000.00
124,086,000.00
120,589,000.00
Total Unusual Items Excluding Goodwill
9,739,000.00
212,000.00
24,234,000.00
--
Total Unusual Items
9,739,000.00
212,000.00
24,234,000.00
--
Normalized EBITDA
158,119,000.00
246,666,000.00
217,285,000.00
220,311,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
2,259,448.00
53,848.00
5,064,906.00
--
3/31/2021 - 12/29/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DSNKY Daiichi Sankyo Company, Limited
32.20
+4.34%
 
OPHLY Ono Pharmaceutical Co., Ltd.
4.8600
+1.46%
 
GLAXF GSK plc
19.85
0.00%
 
DSKYF Daiichi Sankyo Company, Limited
31.85
+5.12%
 
SNPHF Santen Pharmaceutical Co., Ltd.
9.26
0.00%
 
JNJ.MU Johnson & Johnson
137.28
+0.45%
 
SNPHY Santen Pharmaceutical Co., Ltd.
9.39
-1.78%
 
CHGCY Chugai Pharmaceutical Co., Ltd.
15.38
-1.35%
 
OTSKY Otsuka Holdings Co., Ltd.
20.47
+2.20%
 
GRFS Grifols, S.A.
6.38
+1.75%